- Medicare has delayed restrictions on outsourced remote patient monitoring until Jan. 1, 2029, temporarily protecting health technology companies from potentially damaging reimbursement changes.
- The proposed restrictions would limit reimbursement for monitoring services performed by outside contractors, potentially threatening companies dependent on partnerships with medical practices.
- Federal regulators remain concerned about Medicare fraud, questionable billing and insufficient oversight as remote monitoring expenditures grow, leaving the industry’s long-term reimbursement structure uncertain.
The Centers for Medicare & Medicaid Services has postponed a reimbursement change that threatened the business model of remote patient monitoring companies, giving the industry until Jan. 1, 2029, to prepare. The agency had proposed limiting payment for remote physiologic and therapeutic monitoring services to work performed by clinical staff directly employed by medical practices, excluding contracted monitoring personnel. The agency finalized other monitoring requirements for 2027 but delayed this staffing restriction for two years following public comments.
Remote monitoring allows physicians to track patients between appointments using connected devices that transmit measurements such as blood pressure and weight. The industry expanded significantly during the pandemic and attracted substantial venture capital investment. Federal oversight concerns remain significant: An inspector general review found Medicare payments for remote patient monitoring exceeded $500 million in 2024 and flagged billing patterns warranting scrutiny. The postponement preserves existing contractor arrangements temporarily without guaranteeing their long-term survival.
Why It Matters
The delay protects a health technology market from disruption, but it does not settle whether taxpayers should reimburse contractors for services billed through physician practices. Companies built around outsourced monitoring now have time to demonstrate that their services deliver measurable improvements in patient care rather than generating recurring Medicare charges. Investors and medical practices must weigh that opportunity against the risk of a reimbursement change in 2029.
Federal scrutiny is justified. Investigators have identified gaps in oversight, questionable billing patterns and patients who did not receive all expected monitoring components. Protecting Medicare from waste and fraud should remain a priority, but a blanket staffing restriction could also burden smaller practices that lack the resources to operate monitoring programs internally. The sensible path is transparent billing, enforceable clinical standards and payment tied to documented patient benefits. The two-year reprieve provides a chance to establish those safeguards before the restriction takes effect.
Sources
- https://www.wsj.com/pro/venture-capital/remote-patient-monitoring-companies-dodge-medicare-shiftfor-now-73165f70
- https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-medicare-physician-fee-schedule-final-rule
- https://oig.hhs.gov/reports/all/2025/billing-for-remote-patient-monitoring/
- https://www.acponline.org/sites/default/files/documents/advocacy/where_we_stand/assets/cy_27_pfs_proposed_rule_summary_2026.pdf